Cargando…

Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death

Non-small cell lung cancer (NSCLC) prognosis and risk of lymph node positivity (LN+) are reference points for reasonable treatments. The aim of the current study was to investigate the effect of age on LN+ and NSCLC death. Data from the Surveillance, Epidemiology, and End Results (SEER) registry wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Wenjie, Wang, Anpeng, Jin, Meng, Mao, Qixing, Xia, Wenying, Dong, Gaochao, Chen, Bing, Ma, Weidong, Xu, Lin, Jiang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764302/
https://www.ncbi.nlm.nih.gov/pubmed/29386914
http://dx.doi.org/10.2147/CMAR.S152017
_version_ 1783292035824877568
author Xia, Wenjie
Wang, Anpeng
Jin, Meng
Mao, Qixing
Xia, Wenying
Dong, Gaochao
Chen, Bing
Ma, Weidong
Xu, Lin
Jiang, Feng
author_facet Xia, Wenjie
Wang, Anpeng
Jin, Meng
Mao, Qixing
Xia, Wenying
Dong, Gaochao
Chen, Bing
Ma, Weidong
Xu, Lin
Jiang, Feng
author_sort Xia, Wenjie
collection PubMed
description Non-small cell lung cancer (NSCLC) prognosis and risk of lymph node positivity (LN+) are reference points for reasonable treatments. The aim of the current study was to investigate the effect of age on LN+ and NSCLC death. Data from the Surveillance, Epidemiology, and End Results (SEER) registry were used to identify 82,253 patients with NSCLC diagnosed between 1988 and 2008. All the patients underwent standard lung cancer surgery with lymph node examination. Demographic and clinicopathological parameters were extracted and compared among each age group. Impact of age on LN+ and NSCLC death was evaluated by the Cochran–Armitage trend test and logistic univariate and multivariate analyses for all T stages. Overall, 22,711 (27.60%) patients of the entirety had lymph node metastasis and 28,968 (35.22%) patients died of NSCLC within 5 years. With the increase in age, LN+ rates decreased regardless of T stages (P<0.001), whereas NSCLC-specific mortality increased in stages T1–T3 (P<0.001). Controlling other covariates in multivariable logistic regression, age remained an independent risk factor for LN+ in all T stages (P<0.05) and in stages T1–T3 (P<0.05). Our SEER analysis demonstrated a higher rate of LN+ and lower mortality in younger patients with NSCLC, after accounting for other covariates.
format Online
Article
Text
id pubmed-5764302
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57643022018-01-31 Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death Xia, Wenjie Wang, Anpeng Jin, Meng Mao, Qixing Xia, Wenying Dong, Gaochao Chen, Bing Ma, Weidong Xu, Lin Jiang, Feng Cancer Manag Res Original Research Non-small cell lung cancer (NSCLC) prognosis and risk of lymph node positivity (LN+) are reference points for reasonable treatments. The aim of the current study was to investigate the effect of age on LN+ and NSCLC death. Data from the Surveillance, Epidemiology, and End Results (SEER) registry were used to identify 82,253 patients with NSCLC diagnosed between 1988 and 2008. All the patients underwent standard lung cancer surgery with lymph node examination. Demographic and clinicopathological parameters were extracted and compared among each age group. Impact of age on LN+ and NSCLC death was evaluated by the Cochran–Armitage trend test and logistic univariate and multivariate analyses for all T stages. Overall, 22,711 (27.60%) patients of the entirety had lymph node metastasis and 28,968 (35.22%) patients died of NSCLC within 5 years. With the increase in age, LN+ rates decreased regardless of T stages (P<0.001), whereas NSCLC-specific mortality increased in stages T1–T3 (P<0.001). Controlling other covariates in multivariable logistic regression, age remained an independent risk factor for LN+ in all T stages (P<0.05) and in stages T1–T3 (P<0.05). Our SEER analysis demonstrated a higher rate of LN+ and lower mortality in younger patients with NSCLC, after accounting for other covariates. Dove Medical Press 2018-01-08 /pmc/articles/PMC5764302/ /pubmed/29386914 http://dx.doi.org/10.2147/CMAR.S152017 Text en © 2018 Xia et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Xia, Wenjie
Wang, Anpeng
Jin, Meng
Mao, Qixing
Xia, Wenying
Dong, Gaochao
Chen, Bing
Ma, Weidong
Xu, Lin
Jiang, Feng
Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death
title Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death
title_full Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death
title_fullStr Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death
title_full_unstemmed Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death
title_short Young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death
title_sort young age increases risk for lymph node positivity but decreases risk for non-small cell lung cancer death
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764302/
https://www.ncbi.nlm.nih.gov/pubmed/29386914
http://dx.doi.org/10.2147/CMAR.S152017
work_keys_str_mv AT xiawenjie youngageincreasesriskforlymphnodepositivitybutdecreasesriskfornonsmallcelllungcancerdeath
AT wanganpeng youngageincreasesriskforlymphnodepositivitybutdecreasesriskfornonsmallcelllungcancerdeath
AT jinmeng youngageincreasesriskforlymphnodepositivitybutdecreasesriskfornonsmallcelllungcancerdeath
AT maoqixing youngageincreasesriskforlymphnodepositivitybutdecreasesriskfornonsmallcelllungcancerdeath
AT xiawenying youngageincreasesriskforlymphnodepositivitybutdecreasesriskfornonsmallcelllungcancerdeath
AT donggaochao youngageincreasesriskforlymphnodepositivitybutdecreasesriskfornonsmallcelllungcancerdeath
AT chenbing youngageincreasesriskforlymphnodepositivitybutdecreasesriskfornonsmallcelllungcancerdeath
AT maweidong youngageincreasesriskforlymphnodepositivitybutdecreasesriskfornonsmallcelllungcancerdeath
AT xulin youngageincreasesriskforlymphnodepositivitybutdecreasesriskfornonsmallcelllungcancerdeath
AT jiangfeng youngageincreasesriskforlymphnodepositivitybutdecreasesriskfornonsmallcelllungcancerdeath